Results 1 - 10 of 187 : 1 2 3 4 5 6 7 8 9 Next
It's desperate, and the high acquisition price of ImClone shows it.
3 Drugmakers With Multiple Shots on Goal
Well-stocked pipelines could kick these drugmakers into super-high gear.
How to Be Finnished With This Crisis
Let's take a bitter pill for a quick, painful fix and avoid decades of financial agony.
Moody's Gets Moody With Drugmakers
The credit rating agency frowns on European pharmaceuticals.
Are Drug Companies Being Shortsighted With R&D?
Cutting research and development spending is playing with fire.
Drug Duo Combines Its Way Toward an Approval
Bristol-Myers and AstraZeneca are trying to get their diabetes drug approved as a combination treatment.
Direct-to-consumer ads have to walk a line.
Merck and Schering just can't catch a break.
Another FDA Setback for Johnson & Johnson
The company has to wait for an approval of its extended-release schizophrenia drug.
Don't Worry About Vytorin's Cancer Risk
Congress' ramblings are much ado about nothing.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK